Coherus BioSciences Inc (CHRS) — Cash Flow Quality Index
Coherus BioSciences Inc (CHRS) has a Cash Flow Quality Index of -0.08x as of December 2025. Operating cash flow of $-19.72 Million is below net income of $241.20 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow conversion of Coherus BioSciences Inc to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Coherus BioSciences Inc Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for Coherus BioSciences Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check CHRS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Coherus BioSciences Inc (2019–2025)
Year-by-year earnings quality comparison for Coherus BioSciences Inc. For live market cap and the full company financial profile, see Coherus BioSciences Inc (CHRS) market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.82x | $-138.51 Million | $168.02 Million | ▼ -15.0% |
| 2024 | -0.72x | $-20.44 Million | $28.51 Million | ▼ -161.5% |
| 2020 | 1.17x | $154.15 Million | $132.24 Million | ▲ +269.3% |
| 2019 | 0.32x | $28.36 Million | $89.83 Million | — |